{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
maytansine
to a specific field?
Ansamitocin P3, a structural analogue of maytansine, was isolated from Nocardia. Structurally maytansine and ansamitocin P3 are polyketide macrolactams differing in the acyl groups at the C3 position. Ansamitocin P-3 inhibited the polymerization of tubulin and depolymerized the once polymerized tubulin. Ansamitocin P3 exerts antitumour properties.
Status:
US Approved Rx
(2022)
Source:
BLA761310
(2022)
Source URL:
First approved in 2022
Source:
BLA761310
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:izeltabart tapatansine [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00352131: Phase 1 Interventional Completed Non-colorectal Cancer
(2005)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:nendratareotide uzatansine [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT04154956: Phase 3 Interventional Active, not recruiting Non-small Cell Lung Cancer Metastatic
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
